Product Description
Lassen Therapeutics is developing LASN500, an anti-IL18BP for oncology patients. (Sourced from: https://lassentherapeutics.com/pipeline/)
Mechanisms of Action: IL18 Modulator
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lassen Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|